Kaizen Financial Strategies’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Kaizen Financial Strategies’s Portfolio BIB Stock Details BIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$536K	Sell	5,315 -250	-4%	-$21K	0.17%	89
2026 Q1	$483K	Buy	5,565 +250	+5%	+$20.7K	0.2%	89
2025 Q4	$424K	Buy	+5,315	New	+$393K	0.19%	94

Other funds holding BIB

TFA

Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return

ATPW

Ashton Thomas Private Wealth Scottsdale, Arizona $4.79B AUM 27.94% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

AIM

Axiom Investment Management New York $150M AUM

Kaizen Financial Strategies's BIB Position: Q2 2026 in Review

Kaizen Financial Strategies reduced its ProShares Ultra NASDAQ Biotechnology (BIB) stake by 4.5% in Q2 2026, selling an estimated $21K and leaving 5,315 shares worth $536K. The position accounts for 0.17% of the portfolio, ranked #89.

Kaizen Financial Strategies first reported a position in BIB in Q4 2025 and has held it in 3 quarters since. 5 funds tracked by Wall St. Rank hold BIB as of Q2 2026.

Kaizen Financial Strategies held 5,315 shares of ProShares Ultra NASDAQ Biotechnology worth $536K as of Q2 2026.
Kaizen Financial Strategies sold 250 ProShares Ultra NASDAQ Biotechnology shares in Q2 2026, an estimated $21K.
ProShares Ultra NASDAQ Biotechnology made up 0.17% of Kaizen Financial Strategies's portfolio in Q2 2026, its #89 holding.
Kaizen Financial Strategies first reported a position in ProShares Ultra NASDAQ Biotechnology in Q4 2025 and has held it in 3 quarters since.
5 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q2 2026.

Based on Kaizen Financial Strategies's 13F filing for Q2 2026, filed 30 Jul 2026.